Navigation Links
FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
Date:5/13/2008

DELAND, Fla., May 13 /PRNewswire/ -- USHIFU, LLC, the clinical trial management provider for Focus Surgery, Inc. (Indianapolis, IN), is pleased to announce conditional written approval pending minor changes to the protocol from the FDA to begin a pivotal trial for the treatment of recurrent prostate cancer with the Sonablate(R) 500 in men who have failed external beam radiation therapy.

Dr. Herbert Lepor, Chairman of Urology at NYU School of Medicine and medical monitor for the trial said, "It is my pleasure to serve as the medical monitor for the prostate cancer clinical trial program evaluating the safety and effectiveness of the Sonablate(R) 500 HIFU device."

"I have personally reviewed the preliminary data and observed the Sonablate(R) 500 in action and I am impressed with this advanced technology for ablating the prostate. These rigorous clinical trials will help define the appropriate role of the Sonablate(R) 500 device in the treatment of prostate cancer," Lepor added.

This trial will be conducted at various sites across the U.S. and is expected to enroll approximately 202 subjects and 10 clinical centers. This clinical trial is based on results from the feasibility trial completed in October 2007 which enrolled 11 subjects from two clinical research sites within the U.S. Ten of the eleven subjects had failed external beam radiation therapy prior to participating in the clinical trial. The results of this feasibility trial provided a basis for the pivotal study. Additional studies are still needed to satisfy the safety and effectiveness standards, including long term outcomes, set by the FDA for marketing approval.

The Sonablate(R) 500 is not approved for use in the U.S. The Sonablate(R) 500 remains investigational in the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. FDA has made no decision as to the safety or efficacy of the Sonablate(R) 500 for the treatment of prostate canc
'/>"/>

SOURCE USHIFU, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
2. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
3. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
4. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
7. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
8. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
9. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
10. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
11. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  Surgical Theater, LLC announced today the ... Advisory Board. New members include Ori J. ... Development and New Technologies for Given Imaging Ltd., ... Vice President and General Manager of Philips Healthcare,s ... simulation technology to brain surgery and has developed ...
(Date:7/28/2014)... July 28, 2014  Air Products (NYSE: ... medical oxygen is vital to any healthcare facility. This ... not only improve the efficiency of its oxygen supply ... highlight these systems—including systems for emergency oxygen supply ... August 4-5 at the 51 st ASHE ...
(Date:7/28/2014)... -- UBM Medica US announces that Diagnostic Imaging ... professionals, explored the complex situation regarding measuring the ... The shift from fee-for-service has left radiology at a ... determined in the new payment model . ... who recognized the complexity of the radiologist,s value: ...
Breaking Medicine Technology:Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 2Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 3Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 4Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 5Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3Diagnostic Imaging Delves into Measuring the Radiologist's Value 2
... Valeant Pharmaceuticals International, Inc. (the "Company" or "Valeant") ... Intention to make a normal course issuer bid with ... TSX has accepted the Notice of Intention. Under the ... for cancellation, commencing August 25, 2011, 1,000,000 of its ...
... a leading provider of healthcare IT and medical billing solutions, ... 2011 Inc. 5000 list, a compendium of the most entrepreneurial ... the second year in a row that ITelagen qualified for ... position #2093, with an extraordinary four-year growth rate of 120.22%. ...
Cached Medicine Technology:Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid 2Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid 3ITelagen Named to Prestigious 2011 Inc. 5000 List of Fastest-Growing Companies 2
(Date:7/28/2014)... --,The more chronic medical conditions people have at retirement ... new study claims. Since nearly four in ... Johns Hopkins Bloomberg School of Public Health in Baltimore ... life expectancy are slowing in the United States. ... disease and heart failure is now the norm and ...
(Date:7/28/2014)... 2014 (HealthDay News) -- Endurance runners are far more ... heart condition, according to a new study. ... events in warm climates are actually 10 times more ... the less common sudden death of a young and ... as an irregular heartbeat, often gets a lot more ...
(Date:7/28/2014)... Most cells do not divide unless there is enough ... cells and other cell types circumvent this rule. Researchers ... mechanism that overrides the cells, warning signals, enabling cancers ... supply. In the process, the researchers found that lysosomes ... cell division decisions. They also uncovered new evidence that ...
(Date:7/28/2014)... Washington, NY (PRWEB) July 28, 2014 Parker ... many years fighting to ensure that the heroes of 9/11 ... Fund (VCF) has announced an important deadline. According to a ... were diagnosed with a covered cancer on or before October ... October 12, 2014. First responders and others who were allegedly ...
(Date:7/28/2014)... July 28, 2014 The Brooke ... has donated more than 200,000 books to children and ... the launch of Brooke’s Cooks, a new initiative designed ... healthy living among at-risk children and their families in ... a series of nutrition information workshops, cooking demonstrations and ...
Breaking Medicine News(10 mins):Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2Health News:Cell's recycling center implicated in division decisions 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 4
... Rare Diseases, BETHESDA, Md., April 24 ... of Representatives for passing,legislation to reauthorize the Small ... testimony from Robert J. Beall, Ph.D., president and ... requiring that,special attention be given to research for ...
... The following are,excerpts from an article in The ... Republican National Committee:, Congressional Democrats are backing away ... saying that even if,their party controls the White House ... some senators, the promises made by Sens. Barack Obama ...
... (Nasdaq: ONXX ) today announced that it ... Conference on Thursday,May 1, at 8:00 a.m. Eastern ... of the presentation on our website at:, ... listeners log on 15 minutes early in order ...
... how brain cell communication may be altered in schizophrenia ... at the Medical College of Georgia, a 2008 Distinguished ... Alliance Eminent Scholar in Neuroscience and professor in the ... of 11 scientists to receive the award, which includes ...
... Perrigo Company,(Nasdaq: PRGO ; TASE) today announced that ... Administration (FDA) to market over-the-counter (OTC),Nicotine Polacrilex Gum USP, ... The FDA has determined the product to be ... mg (base) and 4 mg,(base), which is an aid ...
... April 24 Karen Ignagni,President and CEO ... issued,the following statement commending the Senate on ... Senate:, (Logo: http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ), ... the basis of their genetic,makeup. We applaud ...
Cached Medicine News:Health News:Cystic Fibrosis Foundation Lauds Congress for Passage of Small Business Innovation Research Program 2Health News:RNC: Dems Hedge on Healthcare 2Health News:Dr. Mei honored by mental health research charity for schizophrenia studies 2Health News:Dr. Mei honored by mental health research charity for schizophrenia studies 3Health News:Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum 2
... Conduit TCP is a synthetic porous ceramic ... similar to the mineral phase that comprises 70% ... that provides a scaffold that allows the attachment ... development of vascular networks within granules as well ...
Schuknecht-Weitlaner retractor, sharp, angled arms....
Weitlaner Beckmann retractor, sharp prongs, SS....
Scoville sharp curette, 10, straight, scoop size 4 x 10 mm....
Medicine Products: